Bausch Health Companies Inc. (TSE:BHC – Get Free Report) insider Mirza Dautbegovic sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the completion of the transaction, the insider directly owned 224,745 shares of the company’s stock, valued at C$2,512,649.10. This represents a 8.17% decrease in their position.
Bausch Health Companies Trading Up 3.3%
TSE BHC traded up C$0.37 on Friday, hitting C$11.56. 852,072 shares of the stock were exchanged, compared to its average volume of 563,138. Bausch Health Companies Inc. has a 52-week low of C$6.10 and a 52-week high of C$12.65. The company has a debt-to-equity ratio of -1,559.86, a current ratio of 1.56 and a quick ratio of 0.58. The company has a market capitalization of C$4.33 billion, a price-to-earnings ratio of -5.12, a P/E/G ratio of 0.21 and a beta of 0.73. The company’s 50-day moving average price is C$8.99 and its two-hundred day moving average price is C$7.98.
Bausch Health Companies (TSE:BHC – Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported C$2.52 earnings per share (EPS) for the quarter. The company had revenue of C$4.19 billion during the quarter. Bausch Health Companies had a positive return on equity of 57.67% and a negative net margin of 7.43%. Research analysts predict that Bausch Health Companies Inc. will post 5.55 EPS for the current year.
Bausch Health Companies declared that its Board of Directors has authorized a share repurchase plan on Wednesday, October 28th that allows the company to buy back C$70 million in outstanding shares. This buyback authorization allows the company to purchase up to 1.9% of its shares through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group raised Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.
Read Our Latest Stock Report on BHC
Bausch Health Companies Company Profile
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Recommended Stories
- Five stocks we like better than Bausch Health Companies
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
